Inhibitors, enzyme proteins

Protein enzyme inhibitors and lectins (hemagglutinins), and their interactions with other molecules, have a broad range of ramifications (Table I). Both classes of proteins are subject to the same set of... 

Protein conformational stability Is not only of fundamental Interest for protein chemistry, but also relevant to questions of food safety and quality. High stability of proteinase Inhibitors may necessitate use of conditions for their Inactivation that denature other proteins first and lead to other reactions that have undesirable consequences for protein digestibility (Richardson, 1977). In discussing Inactivation of enzymes during food processing. Balls (1942) stated, "Until we know more about It, we shall probably overheat our products rather than underheat them, just to be safe. When we know more about It we may be able to moderate our enthusiasm and our technique". Basic studies on stabilities of protein enzyme Inhibitors and lectins, as well as enzymes, can contribute to development of methods that avoid overheating or underheating food or feed products. 

Protein engineering is now routinely used to modify protein molecules either via site-directed mutagenesis or by combinatorial methods. Factors that are Important for the stability of proteins have been studied, such as stabilization of a helices and reducing the number of conformations in the unfolded state. Combinatorial methods produce a large number of random mutants from which those with the desired properties are selected in vitro using phage display. Specific enzyme inhibitors, increased enzymatic activity and agonists of receptor molecules are examples of successful use of this method. 

Cavalli A, Greco G, Novellino E, Recanatini M. Linking CoMFA and protein homology models of enzyme-inhibitor interactions an application to nonsteroidal aromatase inhibitors. Bioorg Med Chem 2000 8 2771-80. 

Apohpoproteins carry out several roles (1) they can form part of the stmcture of the hpoprotein, eg, apo B (2) they are enzyme cofactors, eg, C-11 for lipoprotein hpase, A-1 for lecithinicholesterol acyltransferase, or enzyme inhibitors, eg, apo A-11 and apo C-111 for lipoprotein hpase, apo C-1 for cholesteryl ester transfer protein and (3) they act as hgands for interaction with lipopro-... 

So far, it has been established from in vitro studies that the enzyme undergoes phosphorylation, a process that changes the conformation of the enzyme protein and leads to an increase in its activity. This involves Ca +/calmodulin-dependent protein kinase II and cAMP-dependent protein kinase which suggests a role for both intracellular Ca + and enzyme phosphorylation in the activation of tryptophan hydroxylase. Indeed, enzyme purified from brain tissue innervated by rostrally projecting 5-HT neurons, that have been stimulated previously in vivo, has a higher activity than that derived from unstimulated tissue but this increase rests on the presence of Ca + in the incubation medium. Also, when incubated under conditions which are appropriate for phosphorylation, the of tryptophan hydroxylase for its co-factor and substrate is reduced whereas its Fmax is increased unless the enzyme is purified from neurons that have been stimulated in vivo, suggesting that the neuronal depolarisation in vivo has already caused phosphorylation of the enzyme. This is supported by evidence that the enzyme activation caused by neuronal depolarisation is blocked by a Ca +/calmodulin protein kinase inhibitor. However, whereas depolarisation... 

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers decrease protein excretion and are the drugs of choice for hypertension in patients with CKD. 

Lamotrigine Modulate sodium channels Loading dose Not recommended due to increased risk of rash Maintenance dose 1 50-800 mg/day in 2-3 divided doses. Doses should be initiated and titrated according to the manufacturer s recommendations to reduce the risk of rash Half-life Not established Monotherapy 24 hours Concurrent enzyme inducers 12-15 hours Concurrent enzyme inhibitors 55-60 hours Apparent volume of distribution 1.1 L/kg Protein binding 55% Primary elimination route Hepatic Ataxia, drowsiness, headache, insomnia, sedation Rash... 

As we have just seen, the initial encounter complex between an enzyme and its substrate is characterized by a reversible equilibrium between the binary complex and the free forms of enzyme and substrate. Hence the binary complex is stabilized through a variety of noncovalent interactions between the substrate and enzyme molecules. Likewise the majority of pharmacologically relevant enzyme inhibitors, which we will encounter in subsequent chapters, bind to their enzyme targets through a combination of noncovalent interactions. Some of the more important of these noncovalent forces for interactions between proteins (e.g., enzymes) and ligands (e.g., substrates, cofactors, and reversible inhibitors) include electrostatic interactions, hydrogen bonds, hydrophobic forces, and van der Waals forces (Copeland, 2000). 

In all the treatments of enzyme-inhibitor interactions that we have discussed so far, we assumed that the inhibitor concentration required to achieve 50% inhibition is far in excess of the concentration of enzyme in the reaction mixture. The concentration of inhibitor that is sequestered in formation of the El complex is therefore a very small fraction of the total inhibitor concentration added to the reaction. Hence one may ignore this minor perturbation and safely assume that the concentration of free inhibitor is well approximated by the total concentration of inhibitor (i.e, [7]f [/]T). This is a typical assumption that holds for most protein-ligand binding interactions, as discussed in Copeland (2000) and in Appendix 2. 

---